January 2008 in “Padua Research Archive (University of Padua)” Hereditary factors affect acne duration, not severity, and late-onset acne in females has different causes.
July 2024 in “LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)” Adipose tissue and eccrine gland displacement are common in certain alopecias but don't help differentiate between them.
4 citations
,
January 2019 in “Indian Dermatology Online Journal” The term "Porokeratotic Adnexal Ostial Nevus" is suggested as a more appropriate name.
February 2012 in “Journal of The American Academy of Dermatology” August 2023 in “Journal of The American Academy of Dermatology”
March 2014 in “Journal of The American Academy of Dermatology”
February 2014 in “Journal of The American Academy of Dermatology”
1 citations
,
November 1996 in “Journal of Cutaneous Medicine and Surgery” Hormones, especially androgens, play a key role in causing acne, and treatments like hormone control pills and hormone-blocking medications can help.
6 citations
,
October 2014 in “Experimental Dermatology” Prostaglandins and the enzyme AKR1C3 could play a role in skin cancer and hair loss, and further research is needed to understand these mechanisms.
12 citations
,
August 2011 in “European Journal of Endocrinology” Anti-Müllerian hormone is a specific marker for ovarian issues in women with conditions like PCOS.
April 1977 in “Pediatric Research” 9 citations
,
June 1999 in “Acta Obstetricia Et Gynecologica Scandinavica” Oral contraceptives are effective for treating hyperandrogenism, while ovarian electrocautery is better for women with infertility.
12 citations
,
July 2017 in “International Journal of Cosmetic Science” N‐AOHPA is a promising alternative to traditional surfactants for better hair conditioning.
July 2019 in “Journal of the ASEAN Federation of Endocrine Societies” The woman had a rare adrenal tumor removed, and she recovered well with no signs of the tumor returning.
November 2021 in “International Journal of Trichology” Low PON1 levels may indicate and predict the severity of hair loss.
1 citations
,
December 2020 in “Journal of diabetes and endocrine practice” I'm sorry, but I can't provide a summary without the content of the document.
2 citations
,
June 2009 in “Journal of the American Academy of Dermatology” The treatment didn't work for the woman's hair loss and skin darkening.
4 citations
,
September 2024 in “BMC Cancer” Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
1 citations
,
May 2001 in “Pharmacology & Toxicology” Cyproterone acetate may cause liver cancer at high doses, but is considered safe at recommended doses for approved uses.
January 2026 in “Frontiers in Bioscience-Landmark” Araliadiol protects skin cells from damage by boosting antioxidant defenses.
February 2024 in “International journal of health, medicine and nursing practice” Raising awareness about PCOS can improve women's quality of life.
19 citations
,
October 2015 in “British Journal of Dermatology” Diphenylcyclopropenone's effectiveness and safety for alopecia areata are unclear.
2 citations
,
January 2013 in “International Journal of Dermatology” ALDOA levels drop in hair cells during hair loss.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
August 2024 in “Indian Dermatology Online Journal” DCPA commonly affects males' lower legs, showing follicular pustules and white areas.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
5 citations
,
April 2014 in “European Journal of Obstetrics & Gynecology and Reproductive Biology” AMH levels can't reliably tell the difference between LOCAH and all types of PCOS in women with excessive hair growth.
March 2025 in “Pediatric Dermatology” The supplement aims to improve care for children with alopecia areata.
July 2023 in “Nasza Dermatologia Online” More research is needed on CCCA in children, especially Black and Asian adolescents.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.